Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224178 · ClinicalTrials.gov registry record
Left Atrial Strain and Cryptogenic Stroke
A clinical trial of Hemorrhagic Stroke and Ischemic Stroke, Cryptogenic, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 900
- Enrollment target
- 1
- Study location
NCT07224178 is a study of Hemorrhagic Stroke and Ischemic Stroke, Cryptogenic that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 900 participants, below the 10,248-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07224178, a study of Hemorrhagic Stroke and Ischemic Stroke, Cryptogenic, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke. Current medical guidelines recommend blood-thinning medication (anticoagulation) only when atrial fibrillation (AF) -an irregular heart rhythm- can be documented. However, AF may occur silently and remain undetected. Long term implantable (placed invasively under the skin) devices may be needed to capture these episodes. AF is known to develop from disease of the left atrium, the upper chamber of the heart that receives blood from the lungs. When the left atrium does not contract normally, blood flow may slow down, increasing the risk of clot formation. Nowadays, the left atrial (LA) function can be quantified precisely using a noninvasive ultrasound technique called strain imaging. This study aims to determine whether reduced LA function is associated with cryptogenic stroke and its recurrence even when AF is not observed. If such an association is confirmed, LA strain could serve as a new biomarker to identify patients at risk, earlier than the development of overt AF, enhance preventive measures to reduce recurrent strokes. Because echocardiographic strain imaging is safe, cost-effective, and widely available, it may become an important tool for improving care in this high-risk population.
Conditions Studied
Study Locations (1)
Pennsylvania
- UPMC Presbyterian - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224178
The ClinicalTrials.gov registry entry for NCT07224178 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 10,248-participant average among 6 other Hemorrhagic Stroke trials with a reported enrollment target (91% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Hemorrhagic Stroke appearing as the primary indexed condition, and to 0 interventions.
NCT07224178 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07224178 about?
NCT07224178 is a clinical study titled "Left Atrial Strain and Cryptogenic Stroke". Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke. Current medical guidelines recommend blood-thinning medication (anticoagulation) only when atrial fibrillation (...
What is the current status of trial NCT07224178?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2025-12-17. Estimated completion is 2027-12-31.
What conditions does trial NCT07224178 study?
This clinical trial studies the following conditions: Hemorrhagic Stroke, Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Embolic Stroke of Undetermined Source, Recurrent Ischemic Stroke.
Who is sponsoring clinical trial NCT07224178?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224178 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhagic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
RECRUITING · NA
-
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
RECRUITING · NA
-
Stroke Recovery Initiative - Registry for Stroke Research Studies
RECRUITING
-
Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients
RECRUITING
-
Wireless Nerve Stimulation Device To Enhance Recovery After Stroke
RECRUITING · NA
-
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.